Skip to main content
Gut logoLink to Gut
. 1978 Apr;19(4):330–335. doi: 10.1136/gut.19.4.330

Serum carbenoxolone in patients with gastric and duodenal ulcer: Absorption, efficacy and side-effects.

J H Baron, J N Gribble, C Rhodes, P A Wright
PMCID: PMC1411939  PMID: 648939

Abstract

The absorption of carbenoxolone sodium has been studied in 15 patients with gastric ulcer and eight patients with duodenal ulcer treated for four weeks. Blood levels of carbenoxolone showed a log distribution, varied markedly between patients, and were significantly higher after Biogastrone tablets (300 mg/day) than after Duogastrone capsules (200 mg/day). Serum carbenoxolone levels were similar in patients taking Biogastrone tablets before or after meals, and in patients taking Biogastrone tablets or Duogastrone capsules with or without antacids following chronic administration. Serum carbenoxolone levels were similar in patients whose gastric ulcers had or had not healed after four weeks' treatment. Serum carbenoxolone was significantly higher in patients who developed oedema, and was significantly correlated with age and with fall in plasma potassium. Carbenoxolone may exert its metabolic effects systemically, but its ulcer-healing effects topically; additional studies are needed to test this hypothesis.

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Doll R., Langman M. J., Shawdon H. H. Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. Gut. 1968 Feb;9(1):42–45. doi: 10.1136/gut.9.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Downer H. D., Galloway R. W., Horwich L., Parke D. V. The absorption and excretion of carbenoxolone in man. J Pharm Pharmacol. 1970 Jul;22(7):479–487. doi: 10.1111/j.2042-7158.1970.tb10550.x. [DOI] [PubMed] [Google Scholar]
  3. Lindup W. E., Parke D. V., Colin-Jones D. The absorption of carbenoxolone administered orally as a positioned-release capsule. Gut. 1970 Jul;11(7):555–558. doi: 10.1136/gut.11.7.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Parke D. V., Hunt T. C., Iveson P. The fate of ( 14 C)carbenoxolone in patients with gastric ulcer. Clin Sci. 1972 Sep;43(3):393–400. doi: 10.1042/cs0430393. [DOI] [PubMed] [Google Scholar]
  5. Rhodes C., Wright P. A. A gas chromatographic determination of carbenoxolone in human serum. J Pharm Pharmacol. 1974 Nov;26(11):894–898. doi: 10.1111/j.2042-7158.1974.tb09199.x. [DOI] [PubMed] [Google Scholar]
  6. Turpie A. G., Thomson T. J. Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. Gut. 1965 Dec;6(6):591–594. doi: 10.1136/gut.6.6.591. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES